P-3298, also known as P32/98, Isoleucine-thiazolidide, is a DPP-4 inhibitor potentially for the treatment of type 2 diabetes. P32/98 decreased non-fasting morning blood glucose more effectively in ZR with iIGT than in ZR with mIGT. Compared with study entry, P32/98 improved DNP of blood glucose in ZR with mIGT and nearly normalized DNP in ZR with iIGT. P32/98 significantly reduced triglycerides and non-esterified fatty acids. Intestinal growth was comparable between inhibitor- and placebo-treated fatty rats.

TNCA, also known as Lycoperodine-1, is a high-affinity CaSR ligand (CaSRL) with co-agonist activity. .

AR-R17779 is a selective alpha7 nicotinic agonist (Ki values are 190 and 16000 nM for rat α7 and α4β2 receptors respectively). AR-R17779 improves learning and memory in rats. Treatment with AR-R17779 significantly reduced atherosclerotic plaque area and improved survival of mice. Treatment with AR-R17779 also suppressed abdominal aortic aneurysm formation. Quantitative RT-PCR of the aorta revealed that mRNA expression levels of interleukin-1β, interleukin-6 and NOX2 were significantly decreased in AR-R17779-treated mice compared with Ang II+HFD mice. AR-R17779 treatment also reduced blood pressure and serum lipid levels.

Thiohydantoin, also known as 2-Thiohydantoin and NSC 11772, is a potent inhibitors of mutant IDH1. Thiohydantoin can decrease the cellular concentration of D2HG, reduce the levels of histone methylation, and suppress the proliferation of stem-like cancer cells in BT142 glioma with IDH1 R132H mutation. Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently found in certain cancers such as glioma. With losing the activity of wild-type IDH1, the R132H and R132C mutant proteins can reduce α-ketoglutaric acid (α-KG) to d-2-hydroxyglutaric acid (D2HG).

IR-825 is a near-infrared dye (NIR). IR-825, after encapsulated into nanoparticles may be useful for cancer photothermal and photodynamic therapy. IR-825 nanoparticles showed pH-dependent fluorescence emission and excellent near-infrared (NIR) irradiation of cancer cells targeted in vitro to provide cytotoxicity. IR-825 nanoparticles showed efficient tumor homing together with rapid renal excretion behaviors, as revealed by MR imaging and confirmed by biodistribution measurement. Notably, when irradiated with an 808 nm laser, tumors on mice with IR-825 nanoparticle injection are completely eliminated without recurrence within 60 days, demonstrating the high efficacy of photothermal therapy.

ZK-756326 is a potent, selective and non-peptide CCR8 chemokine receptor agonist. ZK 756326 inhibited the binding of the CCR8 ligand I-309 (CCL1), with an IC(50) value of 1.8 muM. ZK 756326 was a full agonist of CCR8, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.

CAY10499 is a potent and selective monoglyceride lipase inhibitor exhibiting an IC50 of 90 nM for the recombinant enzyme.

Withanolide B is a withanolide that has been found in W. somnifera. Unlike withanolide A, it does not increase glucose uptake in L6 myotubes. In in silico docking studies, withanolide B was identified as a neuronal nitric oxide synthase (nNOS) inhibitor that also inhibited inducible NOS (iNOS) and endothelial NOS and as a ligand for the PARP1 catalytic domain.

REC-2615 (HCl) is a α1B-adrenoceptor antagonist potentially for the treatment of female sexual dysfunction.

Asimadoline HCl is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline has also been shown to be used in the treatment of irritable bowel syndrome.

Examorelin, also known as Hexarelin, is a growth hormone-releasing factor (GHRF) agonist potentially for the treatment of cardiac diseases.

Tocladesine is a cyclic adenosine monophosphate (cAMP) receptor agonist potentially for the treatment of colorectal cancer.

Fluasterone, also known as HE2500, is an NF-κB activation inhibitor potentially for the treatment of metabolic syndrome.

Apratastat, also known as TMI-005 and XMT-1191, is a matrix metalloproteinase/tumour necrosis factor-α convertase inhibitor.

An alpha2-adrenoceptor antagonist potentially for the treatment of schizophrenia.

Sipatrigine is a multiple channels blocker potentially for the treatment of stroke. It has been shown to blocks multiple cardiac ion channels, cause triangulation of the ventricular action potential,and could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1.

Sodium pyruvate is a antioxidant potentially for the treatment of chronic obstructive pulmonary disease

N-Acetylmannosamine, also known as ManNAc, DEX M-74, N-acetyl-D-mannosamine, is a drug potentially for the treatment of hereditary inclusion body myopathy

P-1075, also known as PNU-83757 and U-83757, is a K-ATP channel agonist potentially for the treatment of erectile dysfunction, alopecia and arrhythmia.

FdCyd is a DNA methyltransferase (DNMT) inhibitor potentially for the treatment of solid tumours.

Secoisolarisiresinol diglucoside (SDG) is potentially for the treatment of oxidative stress.

Ferroquine is a hemozoin inhibitor potentially for the treatment of malaria.

Equol is a drug is potentially for the treatment of acute thyroid disease and inhibits proliferation of human gastric carcinoma cells. Equol (racemic) is a mixture of S-equol and R-equol.

Celgosivir is an α-glucosidase inhibitor potentially for the treatment of dengue fever.

Sodium taurocholate is a GPBAR1 protein agonist potentially for the treatment of type 2 diabetes and obesity in rats.

Siramesine Fumarate is a sigma receptor agonist potentially for the treatment of generalized anxiety disorder

NGX-267 is a muscarinic M1 agonist potentially for the treatment of Xerostomia, Alzheimer's disease and cognitive

Pyridoxyl phosphate is a purinergic P2 receptor antagonist potentially for the treatment of tardive dyskinesia

ZD-0947, also known as AZD-0947, is a K(ATP) channel activator potentially for the treatment of overactive bladder (OAB).

Oxipurinol is a xanthine oxidase inhibitor potentially for the treatment of heart failure and gout.